Read by QxMD icon Read

Urologic Oncology

Kohei Hashimoto, Hidetoshi Tabata, Tetsuya Shindo, Toshiaki Tanaka, Jiro Hashimoto, Ryuta Inoue, Takashi Muranaka, Hiroshi Hotta, Masahiro Yanase, Yasuharu Kunishima, Atsushi Takahashi, Naoya Masumori
OBJECTIVE: Our aim was to evaluate the usefulness of serum testosterone to guide treatment decision for castration-resistant prostate cancer (CRPC). METHODS: We conducted a retrospective analysis of 115 patients with CRPC treated with either abiraterone (n = 43) or enzalutamide (n = 72). A serum testosterone level was measured at time of starting of abiraterone or enzalutamide. We determined whether serum testosterone influenced the outcomes of androgen receptor (AR)-targeted therapy...
May 16, 2019: Urologic Oncology
Alp Tuna Beksac, Kennedy E Okhawere, Amr A Elbakry, Bheesham D Dayal, David J Paulucci, Michael B Rothberg, John P Sfakianos, Ronney Abaza, Daniel D Eun, Akshay Bhandari, Ashok K Hemal, James Porter, Ketan K Badani
OBJECTIVE: To determine the safety and efficacy of performing partial nephrectomy (PN) on patients with high nephrometry score tumors. PATIENTS AND METHODS: We used a prospectively maintained multi-institutional kidney cancer database to identify 144 patients with R.E.N.A.L. nephrometry score ≥10 who underwent PN for a cT1-cT2 renal mass. Baseline demographics and clinical characteristics, tumor characteristics, perioperative, and pathological outcomes were analyzed and reported...
May 16, 2019: Urologic Oncology
Sophie Knipper, Felix Preisser, Elio Mazzone, Francesco A Mistretta, Carlotta Palumbo, Zhe Tian, Alberto Briganti, Shahrokh F Shariat, Fred Saad, Derya Tilki, Markus Graefen, Pierre I Karakiewicz
BACKGROUND: Marital status rates may have changed over time in prostate cancer (PC) patients and may have affected cancer-specific mortality (CSM) and other-cause mortality (OCM). METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2015), we identified PC patients who were either married (n = 326,664) or unmarried (n = 106,533). Temporal trends, cumulative incidence plots, as well as multivariable competing risks regression analyses focused on (1) the overall population, (2) D'Amico low-risk N0M0 PC, (3) D'Amico intermediate-risk N0M0 PC, (4) D'Amico high-risk N0M0 PC, (5) N1M0 PC, and (6) M1 PC patients...
May 15, 2019: Urologic Oncology
Alexander Sankin, Damini Chand, Mark Schoenberg, Xingxing Zang
BACKGROUND: High T-cell receptor (TCR) repertoire clonality is associated with clinical response to immune checkpoint blockade in bladder cancer. OBJECTIVE: To determine if TCR repertoire is more clonal in tumors than in benign inflammation. METHODS: We prospectively identified 12 patients with bladder lesions undergoing transurethral resection. Specimens were collected at time of transurethral resection and stored at -80C. DNA was extracted and high throughput DNA sequencing of the CDR3 region of the TCR beta chain using the immunoSEQ assay (Adaptive Biotechnologies) was performed...
May 15, 2019: Urologic Oncology
Ellen Westhoff, Ellen Kampman, Katja K Aben, Inge G Hendriks, Johannes Alfred Witjes, Lambertus A Kiemeney, Alina Vrieling
BACKGROUND: A healthy lifestyle may reduce the risk of non-muscle-invasive bladder cancer (NMIBC) recurrence. The objective of this study was to obtain insight in whether NMIBC patients are aware of possible risk factors for (bladder) cancer, adhere to lifestyle recommendations for cancer prevention, received lifestyle advice from their physician, and what their attitudes are towards physicians giving lifestyle advice. METHODS: Patients with newly diagnosed NMIBC between 2014 and 2017 participating in the UroLife cohort study completed questionnaires at 6 weeks and 3 months after diagnosis about awareness of (bladder) cancer risk factors, adherence to lifestyle recommendations, reception of lifestyle advice, and attitudes towards physicians giving lifestyle advice...
May 8, 2019: Urologic Oncology
Azadeh Nazemi, Saum Ghodoussipour, Shane Pearce, Sumeet Bhanvadia, Siamak Daneshmand
OBJECTIVES: Bladder cancer is the fourth most common cancer among males and poses a significant financial burden, yet there are no large-scale studies focused on the correlation between socioeconomic (SES) and insurance status and bladder cancer outcomes. The objective of this study was to determine the effect of SES and insurance type on outcomes in bladder cancer. MATERIALS AND METHODS: A population-based search was performed using the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 database...
May 8, 2019: Urologic Oncology
Alberto Martini, John P Sfakianos, David J Paulucci, Ronney Abaza, Daniel D Eun, Akshay Bhandari, Ashok K Hemal, Ketan K Badani
BACKGROUND: Acute Kidney Injury (AKI) is a common occurrence after partial nephrectomy and is a significant risk factor for chronic kidney disease. We aimed to create a model that predicts postoperative AKI in patients undergoing robot-assisted partial nephrectomy (RAPN). METHODS: We identified 1,190 patients who underwent RAPN between 2008 and 2017 from a multicenter database. AKI was defined as a >25% reduction in eGFR from pre-RAPN to discharge. A nomogram was built based on a binary logistic regression that ultimately included age, sex, BMI, diabetes, baseline eGFR, and RENAL Nephrometry score...
May 7, 2019: Urologic Oncology
Karen M Xu, Ronald C Chen, David M Schuster, Ashesh B Jani
This review summarizes novel imaging in the management of prostate cancer including multiparametric MRI, PET-CT scans with different radiotracers including 11 C-acetate, 11 C-choline, 18 F-choline, 18 F sodium fluoride, prostate-specific membrane antigen, and anti-1-amino-3-[18F] fluorocyclobutane-1-carboxylic acid (fluciclovine).
May 6, 2019: Urologic Oncology
Georg C Hutterer, Florian Posch, Lorenz Buser, Richard Zigeuner, Laura Morshäuser, Wolfgang Otto, Peter J Wild, Maximilian Burger, Matthias May, Martin Pichler, Sabine D Brookman-May
BACKGROUND: To externally validate' BioScore', a biomarker-based scoring system using immunohistochemical tumor expression levels of B7-H1, survivin, and Ki-67, in a single-center cohort of renal cell carcinoma (RCC) patients. Additionally, we investigated the potential benefit of BioScore as compared to the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score. MATERIALS AND METHODS: The validation cohort comprised 393 nonmetastatic RCC patients treated with radical nephrectomy or nephron-sparing surgery from 1999 to 2004...
May 3, 2019: Urologic Oncology
Robert T Dess, Payal D Soni, William C Jackson, Alejandro Berlin, Brett W Cox, Shruti Jolly, Jason A Efstathiou, Felix Y Feng, Amar U Kishan, Bradley J Stish, Thomas M Pisansky, Daniel E Spratt
Interstitial brachytherapy is one of several curative therapeutic options for the treatment of localized prostate cancer. In this review, we summarize all available randomized data to support the optimal use of prostate brachytherapy. Evidence from completed randomized controlled trials is the focus of this review with a presentation also of important ongoing trials. Gaps in knowledge are identified where future investigation may be fruitful with intent to inspire well-designed prospective studies with standardized treatment that focuses on improving oncological outcomes, reducing morbidity, or maintaining quality of life...
May 3, 2019: Urologic Oncology
Marieke J Krimphove, Alexander P Cole, David F Friedlander, David-Dan Nguyen, Stuart R Lipsitz, Paul L Nguyen, Kerry L Kilbridge, Adam S Kibel, Luis A Kluth, Quoc-Dien Trinh
BACKGROUND: A considerable number of prostate cancer (PCa) patients eligible for expectant management receive definitive treatment. We aimed to investigate the hospital-level contribution to overtreatment in the United States. METHODS: Using the National Cancer Database we identified two nonoverlapping cohorts: (1) men with a life expectancy <10 years harbouring low or intermediate risk PCa (2) men with life expectancy ≥10 years with low-risk PCa. Multivariable mixed models with patient characteristics as fixed and hospital-level intercept as random effect were used to assess the hospital-level risk-adjusted probability of definitive treatment in both groups...
May 2, 2019: Urologic Oncology
Petter Kollberg, Gunilla Chebil, Pontus Eriksson, Gottfrid Sjödahl, Fredrik Liedberg
OBJECTIVES: To investigate the preoperative prognostic value of molecular subtypes in relation to clinical information, histopathological findings, and molecular markers for patients with bladder cancer treated with radical cystectomy. PATIENTS AND METHODS: After standard preoperative staging, a population-based cohort of 519 patients underwent radical cystectomy between 2006 and 2011. Following pathological review of all transurethral resection of bladder tumor specimens, tissue microarrays were constructed, and RNA was extracted from formalin-fixed tissue blocks...
May 2, 2019: Urologic Oncology
Jacob J Adashek, Andrea Necchi, Philippe E Spiess
Penile cancer is a rare, but increasingly more common diagnosis. Although more there are more cases of penile cancer being diagnosed (the incidence is increasing), mortality (or conversely overall survival) has not changed. A detailed discussion of current treatments, along with potential therapeutic targets, and ongoing clinical trials is presented. This review gives insight to treatment strategies and novel modalities to combat a disease with sparse therapeutic options.
May 1, 2019: Urologic Oncology
Liam C Macleod, Jonathan G Yabes, Michelle Yu, Mina M Fam, Nathan E Hale, Robert M Turner, Samia H Lopa, Jeffrey R Gingrich, Tudor Borza, Ted A Skolarus, Benjamin J Davies, Bruce L Jacobs
INTRODUCTION: Contemporary guidelines recommend cystectomy with neoadjuvant or adjuvant cisplatin-based chemotherapy given with curative intent for patients with resectable muscle-invasive bladder cancer (MIBC). However, rates and appropriateness of perioperative chemotherapy utilization remain unclear. We therefore sought to characterize use of perioperative chemotherapy in older radical cystectomy MIBC patients and examine factors associated with use. METHODS: Using Surveillance, Epidemiology, and End Results (SEER)-Medicare data, we identified patients with MIBC diagnosed between 2004 and 2013 and treated with radical cystectomy...
April 30, 2019: Urologic Oncology
Ruben D Vromans, Mies C van Eenbergen, Steffen C Pauws, Gijs Geleijnse, Henk G van der Poel, Lonneke V van de Poll-Franse, Emiel J Krahmer
CONTEXT: Despite increasing interest in the development and use of decision aids (DAs) for patients with localized prostate cancer (LPC), little attention has been paid to communicative aspects (CAs) of such tools. OBJECTIVE: To identify DAs for LPC treatment, and review these tools for various CAs. MATERIALS AND METHODS: DAs were identified through both published literature (MEDLINE, Embase, CINAHL, CENTRAL, and PsycINFO; 1990-2018) and online sources, in compliance with the Preferred Reporting Items for Systematic Review and Meta-Analyses guidelines...
April 30, 2019: Urologic Oncology
Takuya Tsujino, Kazumasa Komura, Takeshi Hashimoto, Ryu Muraoka, Naoya Satake, Tomohisa Matsunaga, Takeshi Tsutsumi, Yuki Yoshikawa, Tomoaki Takai, Koichiro Minami, Hirofumi Uehara, Hajime Hirano, Hayahito Nomi, Naokazu Ibuki, Kiyoshi Takahara, Teruo Inamoto, Yoshio Ohno, Haruhito Azuma
INTRODUCTION: The C-reactive protein to albumin ratio (CAR) has been shown to provide prognostic information in several cancers. The objective in the study is to examine the prognostic value of CAR in patients with RCC who underwent nephrectomy. MATERIAL AND METHODS: The record data from multi-institutional study of 1,028 patients was analyzed in the study. The cut-off value of the CAR was defined by receive operating characteristic (ROC) analysis. Overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were evaluated, and univariate and multivariate analyses were conducted to assess the predictive value of the variables including CAR...
April 30, 2019: Urologic Oncology
Yong-Moon Lee, Jin Man Kim, Hyo Jin Lee, In-Ock Seong, Kyung-Hee Kim
PURPOSE: The aim of our study was to investigate the clinicopathologic values of the expression of CD44, matrix metalloproteinase (MMP)2, and MMP9 in renal cell carcinoma (RCC). PATIENTS AND METHODS: A total of 107 clear cell RCCs (ccRCCs) and 32 nonclear cell RCCs (non-ccRCCs) were examined for CD44, MMP2, and MMP9 expression by immunohistochemistry. The membrane and cytoplasmic expression levels of the 3 proteins were scored by semiquantitative methods, and the correlations of the 3 proteins with clinicopathological parameters were verified...
April 30, 2019: Urologic Oncology
Ulrich Krafft, Stephan Tschirdewahn, Jochen Hess, Nina N Harke, Boris Hadaschik, Csilla Olah, Susanne Krege, Peter Nyirády, Attila Szendröi, Miklós Szücs, Orsolya Módos, Eszter Székely, Henning Reis, Tibor Szarvas
OBJECTIVES: Cisplatin-based chemotherapy represents the gold standard in the treatment of advanced bladder cancer (BC) both in the neoadjuvant and adjuvant setting. Since novel immunooncologic agents are available for cisplatin-resistant or ineligible patients, biological markers for the prediction of cisplatin resistance become more important in treatment decisions. Therefore, we aimed to assess the therapy predictive value of 8 promising tissue biomarkers with regard to cisplatin therapy...
April 30, 2019: Urologic Oncology
Lars Henning Schmidt, Sebastian Huss, Christoph Schuelke, Arik Schulze, Georg Evers, Christoph Schliemann, Anna Hansmeier, Bengt Schilling, Berit Lauterbach, Peter Barth, Karsten Wiebe, Dennis Goerlich, Wolfgang E Berdel, Gerald Puehse, Michael Mohr
OBJECTIVES: In patients with testicular Germ Cell Tumors (GCT) noncaseating granulomatous diseases such as Sarcoid Like Lesions (SLL) or Sarcoidosis can mimic metastasis due to hilar or mediastinal lymphadenopathy. Due to the clinical and prognostic impact, exclusion of malignant diseases is mandatory. MATERIAL AND METHODS: Retrospectively, data from 636 GCT patients, who were seen in the course of tumor surveillance/follow-up were collected. Focus was put on the detection of tumor relapse vs...
April 30, 2019: Urologic Oncology
Andrea Necchi, Salvatore Lo Vullo, Luigi Mariani, Yao Zhu, Ding-Wei Ye, Antonio A Ornellas, Nick Watkin, Michael Ager, Oliver W Hakenberg, Axel Heidenreich, Daniele Raggi, Mario Catanzaro, Roberto Salvioni, Juan Chipollini, Mounsif Azizi, Philippe E Spiess
OBJECTIVES: To improve the prognostic allocation of patients with penile squamous-cell carcinoma (PSCC) receiving regional lymph node dissection (LND). PATIENTS AND METHODS: An international, multicenter, retrospective study was performed on patients with PSCC who received regional LND, with or without perioperative therapy, from 1980 to 2017. We first used a random forest (RF) method with missing data imputation. Additionally, data were modeled using Cox proportional hazard regression, and a Cox model was also fit including prespecified variables...
April 30, 2019: Urologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"